Press Releases

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--May 9, 2023-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications

SEATTLE --(BUSINESS WIRE)--May 4, 2023-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023 , on Tuesday, May 9, 2023 , after the market closes. Omeros management will host a conference call and

At lowest planned subcutaneous dose, Omeros’ MASP-3 inhibitor OMS906 showed clinically and statistically significant improvements in hemoglobin and LDH, which were seen early and maintained throughout the observation period Following 2 doses of OMS906, all patients achieved an increase in

–   Directs Company to Advance its Lead Proprietary PDE7 Inhibitor to Treat Cocaine Use Disorder – SEATTLE --(BUSINESS WIRE)--Apr. 10, 2023-- Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Mar. 13, 2023-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications

SEATTLE --(BUSINESS WIRE)--Mar. 10, 2023-- Omeros Corporation (Nasdaq: OMER), in response to investor inquiries, is confirming that it has no banking or other financial relationship with Silicon Valley Bank . Omeros previously maintained a line of credit with Silicon Valley Bank , which the company

SEATTLE --(BUSINESS WIRE)--Mar. 7, 2023-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2022 , on Monday, March 13, 2023 , after the market closes.

– OMIDRIA ® -Related Payment Expected to Provide Operating Capital into at Least 2025 – SEATTLE --(BUSINESS WIRE)--Feb. 6, 2023-- Omeros Corporation (Nasdaq: OMER) today announced that Rayner Surgical, Inc. (“Rayner”) has paid the $200 million milestone payment due to Omeros under the Asset